Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 5, 2003, Pages 731-740

  Leo, Albrecht ^a   Winteroll, Susanne ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; GANGRENE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGY; LABORATORY DIAGNOSIS; LUNG EMBOLISM; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SHORT SURVEY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HUMANS; IMMUNOASSAY; PLATELET ACTIVATION; PLATELET AGGREGATION; THROMBOCYTOPENIA;

EID: 0141788164     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.5.731-740.2003     Document Type: Short Survey

References (80)

1. Alving, B. M. 2003. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 101:31-37.
2. Amiral, J., F. Bridey, M. Dreyfus, A. M. Vissoc, E. Fressinaud, M. Wolf, and D. Meyer. 1992. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemost. 68:95-96.
3. Amiral, J., F. Bridey, M. Wolf, C. Boyer-Neumann, E. Fressinaud, A. M. Vissac, E. Peynaud-Debayle, M. Dreyfus, and D. Meyer. 1995. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb. Haemost. 73:21-28.
4. Amiral, J., A. Marfaing-Koka, M. Wolf, M. C. Alessi, B. Tardy, C. Boyer-Neumann, A. M. Vissac, E. Fressinaud, M. Poncz, and D. Meyer. 1996. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 88:410-416.
5. Amiral, J., M. Wolf, A. Fischer, C. Boyer-Neumann, A. Vissac, and D. Meyer. 1996. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br. J. Haematol 92:954-959.
6. Arepally, G., C. Reynolds, A. Tomaski, J. Amiral, A. Jawad, M. Poncz, and D. B. Cines. 1995. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am. J. Clin. Pathol. 104:648-654.
7. Bauer, T. L., G. Arepally, B. A. Konkle, B. Mestichelli, S. S. Shapiro, D. B. Cines, M. Poncz, S. McNulty, J. Amiral, W. W. Hauck, R. N. Edie, and J. D. Mannion. 1997. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242-1246.
8. Bichler, J., and H. Fritz. 1991. Hirudin, a new therapeutic tool? Ann. Hematol. 63:67-76.
9. Chong, B. H., J. Burgess, and F. Ismail. 1993. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb. Haemost. 69:344-350.
10. Chong, B. H., and H. N. Magnani. 2001. Danaparoid for the treatment of heparin-induced thrombocytopenia, p. 323. In T. E. Warkentin and A. Greinacher (ed.), Heparin-induced thrombocytopenia, 2nd ed. Marcel Dekker, New York, N.Y.
11. Chong, B. H., and H. N. Magnani. 1992. Orgaran in heparin-induced thrombocytopenia. Haemostasis 22:85-91.
12. Eichler, P., U. Budde, S. Haas, H. Kroll, R. M. Loreth, O. Meyer, U. Pachmann, B. Potzsch, A. Schabel, D. Albrecht, and A. Greinacher. 1999. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/ heparin ELISA. Thromb. Haemost. 81:625-629.
13. Eichler, P., H. J. Friesen, N. Lubenow, B. Jaeger, and A. Greinacher. 2000. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 96:2373-2378.
14. Eichler, P., R. Raschke, N. Lubenow, O. Meyer, P. Schwind, and A. Greinacher. 2002. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br. J. Haematol. 116:887-891.
15. Greinacher, A., J. Amiral, V. Dummel, A. Vissac, V. Kiefel, and C. Mueller-Eckhardt. 1994. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 34:381-385.
16. Greinacher, A., P. Eichler, N. Lubenow, H. Kwasny, and M. Luz. 2000. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846-851.
17. Greinacher, A., U. Janssens, G. Berg, M. Bock, H. Kwasny, B. Kemkes-Matthes, P. Eichler, H. Volpel, B. Potzsch, M. Luz, et al. 1999. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100:587-593.
18. Greinacher, A., and N. Lubenow. 2002. Heparininduzierte Thrombozytopenie. Die gelben Hefte 42:61-70.
19. Greinacher, A., I. Michels, V. Kiefel, and C. Mueller-Eckhardt. 1991. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb. Haemost. 66:734-736.
20. Greinacher, A., and T. E. Warkentin. 2001, Treatment of heparin-induced thrombocytopenia: an overview, p. 291-322. In T. E. Warkentin and A. Greinacher (ed.), Heparin-induced thrombocytopenia., 2nd ed. Marcel Dekker, New York, N.Y.
21. Griffiths, E., and W. H. Dzik. 1997. Assays for heparin-induced thrombocytopenia. Transfus. Med. 7:1-11.
22. Harenberg, J., G. Huhle, C. Giese, L C. Wang, M. Feuring, X. H. Song, and U. Hoffmann. 2000. Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. Br. J. Haematol. 109:182-186.
23. Harenberg, J., L. Wang, U. Hoffmann, G. Huhle, and M. Feuring. 2001. Improved laboratory confirmation of heparin-induced thrombocytopenia type II. Time course of antibodies and combination of antigen and biologic assays. Am. J. Clin. Pathol. 115:432-438.
24. Harenberg, J., L. C. Wang, U. Hoffmann, G. Huhle, and M. Feuring. 2001. Laboratory diagnosis of heparin-induced thrombocytopenia type II after clearance of platelet factor 4/heparin complex. J. Lab. Clin. Med. 137:408-413.
25. a. Harenberg, J., G. Huhle, C. Giese, L. C. Wang, M. Feuring, X. H. Song, and U. Hoffmann. 2000. Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. Br. J. Haematol. 109:182-186.
26. Huhle, G., U. Hoffmann, X. Song, L. C. Wang, D. L. Heene, and J. Harenberg. 1999. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br. J. Haematol. 106:195-201.
27. Izban, K. F., H. W. Lietz, D. A. Hoppensteadt, W. P. Jeske, J. Fareed, M. Bakhos, and J. M. Walenga. 1999. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin. Thromb. Hemost. 25:51-56.
28. Jackson, M. R., C. Krishnamurti, C. A. Aylesworth, and B. M. Alving. 1997. Diagnosis of heparin-induced thrombocytopenia in the vascular surgery patient. Surgery 121:419-424.
29. Jy, W., W. W. Mao, L. L. Horstman, P. A. Valant, and Y. S. Ahn. 1999. A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb. Haemost. 82:1255-1259.
30. Kelton, J. G., D. Sheridan, H. Brain, P. J. Powers, A. G. Turpie, and C. J. Carter. 1984. Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J. Lab. Clin. Med. 103:606-612.
31. a. Koch, S., J. Harenberg, M. Odel, H. Schmidt-Gayk, S. Walch, and U. Budde. 2002. Development of a high-pressure liquid chromatography method for diagnosis of heparin-induced thrombocytopenia. Am. J. Clin. Pathol. 117: 900-904.
32. Koster, A., M. Loebe, R. Hansen, M. Bauer, F. Mertzlufft, H. Kuppe, and R. Hetzer. 2000. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: adaptation of the ecarin clotting time to the act II device. J. Thorac. Cardiovasc. Surg. 119:1278-1283.
33. Laposata, M., D. Green, E. M. Van Cott, T. W. Barrowcliffe, S. H. Goodnight, and R. C. Sosolik. 1998. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch. Pathol. Lab. Med. 122:799-807.
34. Latham, P., A. F. Revelis, G. P. Joshi, J. M. DiMaio, and M. E. Jessen. 2000. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology 92:263-266.
35. Lee, D. H., T. E. Warkentin, G. A. Denomme, C. P. Hayward, and J. G. Kelton. 1996. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br. J. Haematol. 95:724-731.
36. Lewis, B. E., D. E. Wallis, S. D. Berkowitz, W. H. Matthai, J. Fareed, J. M. Walenga, J. Bartholomew, R. Sham, R. G. Lerner, Z. R. Zeigler, P. K. Rustagi, I. K. Jang, S. D. Rifkin, J. Moran, M. J. Hursting, and J. G. Kelton, 2001. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838-1843.
37. Lindhoff-Last, E., G. P. Piechottka, F. Rabe, and R. Bauersachs. 2000. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb. Res. 100:55-60.
38. Lindhoff-Last, E., A. Willeke, C. Thalhammer, G. Nowak, and R. Bauersachs. 2000. Hirudin treatment in a breastfeeding woman. Lancet 355:467-468.
39. Look, K. A., M. Sahud, S. Flaherty, and J. L. Zehnder. 1997. Heparin-induced platelet aggregation vs platelet factor 4 enzyme-linked immunosorbent assay in the diagnosis of heparin-induced thrombocytopenia-thrombosis. Am. J. Clin. Pathol. 108:78-82.
40. Lubenow, N., and A. Greinacher. 2000. Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin. J. Thromb. Thrombolysis 10:47-57.
41. Meyer, O., A. Salama, N. Pittet, and P. Schwind. 1999. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet 354:1525-1526.
42. Newman, P. M., R. L. Swanson, and B. H. Chong. 1998. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb. Haemost. 80:292-297.
43. Parent, F., F. Bridey, M. Dreyfus, D. Musset, G. Grimon, P. Duroux, D. Meyer, and G. Simonneau. 1993. Treatment of severe venous thromboembolism with intravenous Hirudin (HBW 023): an open pilot study. Thromb. Haemost. 70:386-388.
44. Poetzsch, B., and K. Madlener. 1997. Antikoagulationsregime mit Hirudin während des kardiopulmonalen Bypass, p. 17. In Workshop "Heparin-induzierte Thrombozytopenie in der Herzchirurgie." Kerckhoff Clinics, Bad Nauheim, Germany.
45. Poley, S., and W. Mempel. 2001. Laboratory diagnosis of heparin-induced thrombocytopenia: advantages of a functional flow cytometric test in comparison to the heparin-induced platelet-activation test. Eur. J. Haematol. 66:253-262.
46. Potzseh, B., S. Hund, K. Madlener, C. Unkrig, and G. Muller-Berghaus. 1997. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb. Res. 86:373-383.
47. Potzsch, B., W. P. Klovekorn, and K. Madlener. 2000. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N. Engl. J. Med. 343:515.
48. Potzsch, B., K. Madlener, C. Seelig, C. F. Riess, A. Greinacher, and G. Muller-Berghaus. 1997. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time. Thromb. Haemost. 77:920-925.
49. Pouplard, C., J. Amiral, J. Y. Borg, A. M. Vissac, B. Delahousse, and Y. Gruel. 1997. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br. J. Haematol. 99:273-280.
50. Riess, F. C., C. Lower, C. Seelig, N. Bleese, J. Kormann, G. Muller-Berghaus, and B. Potzsch. 1995. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J. Thorac. Cardiovasc. Surg. 110:265-267.
51. Rugeri, L., A. Bauters, N. Trillot, S. Susen, C. Decoen, A. Watel, and B. Jude. 1999. Hemostasis and thrombosis: clinical usefulness of combined use of platelet aggregation test and anti PF4-H antibodies Elisa test for the diagnosis of heparin induced thrombocytopenia. Hematology 4:367-372.
52. Sheridan, D., C. Carter, and J. G. Kelton. 1986. A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27-30.
53. Stewart, M. W., W. S. Etches, L. K. Boshkov, and P. A. Gordon. 1995. Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregometry. Br. J. Haematol. 91:173-177.
54. Swan, S. K., and M. J. Hursting. 2000. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20:318-329.
55. Tardy, B., B. Tardy-Poncet, P. Fournel, C. Venet, R. Jospe, and A. Dacosta. 1999. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb. Haemost. 82:1199-1200.
56. Tomer, A. 1997. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br. J. Haematol. 98: 648-656.
57. Vanholder, R., A. Camez, N. Veys, A. Van Loo, A. M. Dhondt, and S. Ringoir. 1997. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb. Haemost. 77:650-655.
58. Vanholder, R. C., A. A. Camez, N. M. Veys, J. Soria, M. Mirshahi, C. Soria, and S. Ringoir. 1994. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int. 45:1754-1759.
59. Visentin, G. P., S. E. Ford, J. P. Scott, and R. H. Aster. 1994. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J. Clin. Investig. 93:81-88.
60. Vitale, M., P. Tazzari, F. Ricci, M. A. Mazza, G. Zauli, G. Martini, L. Caimi, F. A. Manzoli, and R. Conte. 2001. Comparison between different laboratory tests for the detection and prevention of heparin-induced thrombocytopenia. Cytometry 46:290-295.
61. Vun, C. M., S. Evans, and C. N. Chesterman. 2001. Anti-PF4-heparin immunoglobulin G is the major class of heparin-induced thrombocytopenia antibody: findings of an enzyme-linked immunofiltration assay using membrane-bound hPF4-heparin. Br. J. Haematol. 112:69-75.
62. Walenga, J. M., W. P. Jeske, A. R. Fasanella, J. J. Wood, S. Ahmad, and M. Bakhos. 1999. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin. Appl. Thromb. Hemost. 5:S21-S27.
63. Walenga, J. M., W. P. Jeske, A. R. Fasanella, J. J. Wood, and M. Bakhos, 1999. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin. Thromb. Hemost. 25:43-49.
64. Walenga, J. M., W. P. Jeske, J. J. Wood, S. Ahmad, B. E. Lewis, and M, Bakhos. 1999. Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin. Hematol. 36:22-28.
65. Wallis, R. B. 1996. Hirudins: from leeches to man. Semin. Thromb. Hemost. 22:185-196.
66. Wang, L., G. Huhle, R. Malsch, U. Hoffmann, X. Song, and J. Harenberg. 1999. Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA). J. Immunol. Methods 222:93-99.
67. Wang, L. C., G. Huhle, R. Malsch, V. Hoffmann, X. L. Song, and J. Harenberg. 1999. Determination of heparin-induced IgG antibody in heparin-induced thrombocytopenia type II. Eur. J. Clin. Investig. 29:232-237.
68. Warkentin, T. E. 2001. Clinical picture of heparin-induced thrombocytopenia, p. 43-86. In T. E. Warkentin and A. Greinacher (ed.), Heparin-induced thrombocytopenia., 2nd ed. Marcel Dekker, New York, N.Y.
69. Warkentin, T. E. 1999. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu. Rev. Med. 50:129-147.
70. Warkentin, T. E. 1996. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus. Med. Rev. 10:249-258.
71. Warkentin, T. E. 1997. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Safety 17:325-341.
72. Warkentin, T. E. 2000. Laboratory testing for heparin-induced thrombocytopenia. J. Thromb. Thrombolysis 10:35-45.
73. Warkentin, T. E., B. H. Chong, and A. Greinacher. 1998. Heparin-induced thrombocytopenia: towards consensus. Thromb. Haemost. 79:1-7.
74. Warkentin, T. E., L. J. Elavathil, C. P. Hayward, M. A. Johnston, J. I. Russett, and J. G. Kelton. 1997. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. 127: 804-812.
75. Warkentin, T. E., and A. Greinacher. 2000. Laboratory testing for heparin-induced thrombocytopenia, p. 211-244. In T. E. Warkentin and A. Greinacher (ed.), Heparin-induced thrombocytopenia. Marcel Dekker, New York, N.Y.
76. Warkentin, T. E., C. P. Hayward, C. A. Smith, P. M. Kelly, and J. G. Kelton. 1992. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J. Lab. Clin. Med. 120:371-379.
77. Warkentin, T. E., and J. G. Kelton. 1996. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101:502-507.
78. Warkentin, T. E., and J. G. Kelton. 2001. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344:1286-1292.
79. Warkentin, T. E., M. N. Levine, J. Hirsh, P. Horsewood, R. S. Roberts, M. Gent, and J. G. Kelton. 1995. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332:1330-1335.
80. Warkentin, T. E., J.-A. I. Sheppard, P. Horsewood, P. J. Simpson, J. C. Moore, and J. G. Kelton. 2000. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:1703-1708.